Pfizer’s Prevnar 20 May Have Edge Over Merck’s Pneumococcal Vaccine, ACIP Suggests
CDC advisory committee work group concludes benefits of Merck’s PVC15 in those 65 and older is small while benefits of Pfizer’s PVC20 in those 50 and older is large and in those 65 and older is moderate to large.
You may also be interested in...
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.